Physician profile
Henry Yee
NPI 1285724724
$257,628.15
in general payments reported to CMS, 2019-2025
55 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $25K · 2021: $42K · 2022: $38K · 2023: $54K · 2024: $37K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Honoraria: $17K · Food and Beverage: $14K · Consulting Fee: $7,008 · Travel and Lodging: $4,205 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,128.00 |
| Honoraria | $17,120.00 |
| Food and Beverage | $14,498.66 |
| Consulting Fee | $7,008.00 |
| Travel and Lodging | $4,204.74 |
| Education | $118.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $69,956.96 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Esperion Therapeutics, INC. | $43,305.70 | 2020-2025 | Nexletol, Nexlizet |
| Amgen INC. | $23,545.89 | 2019-2025 | Repatha, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20,179.63 | 2019-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $20,054.05 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $19,162.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $12,715.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $9,541.76 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $8,389.40 | 2019-2022 | |
| Abbott Laboratories | $7,551.10 | 2019-2025 | Gallant, Confirm Rx, Jot Dx |
| Merck Sharp & Dohme LLC | $7,507.40 | 2021-2025 | Verquvo, Steglatro, Capvaxive |
| Lilly USA, LLC | $3,854.23 | 2019-2023 | Jardiance |
| Medtronic, INC. | $1,858.95 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Abbvie INC. | $1,281.45 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Pharmaceuticals, INC | $1,270.95 | 2019-2024 | Xarelto |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,110.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $874.57 | 2021-2025 | Emblem Mri S-Icd, Bodyguardian, Accolade Sr |
| Medtronic Vascular, INC. | $727.38 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $358.28 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $319.56 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $314.24 | 2019-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $289.94 | 2021-2022 | |
| Cardiva Medical, INC. | $282.00 | 2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Mylan Specialty L.P. | $252.85 | 2020-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.05 | 2019-2022 | |
| Vivus LLC | $231.49 | 2023-2025 | Pancreaze |
| Pfizer INC. | $229.10 | 2019-2021 | |
| Novo Nordisk INC | $225.59 | 2020-2025 | Rybelsus, Ozempic |
| Atricure, INC. | $192.14 | 2025 | Atriclip Laa Exclusion System |
| Radius Health, INC. | $185.21 | 2019 | |
| Madrigal Pharmaceuticals | $174.83 | 2024-2025 | Resmetirom, Rezdiffra |
| Sunovion Pharmaceuticals INC. | $169.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $161.18 | 2021-2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $157.32 | 2025 | Sapien 3 Ultra Resilia |
| Dexcom, INC. | $99.20 | 2023 | Dexcom G7 Gss (161) |
| Kowa Pharmaceuticals America, INC. | $89.75 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.47 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $77.53 | 2024 | Arcalyst |
| Corcept Therapeutics | $70.84 | 2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $69.70 | 2019 | |
| Cvrx, INC. | $54.76 | 2022 | |
| Abiomed | $53.89 | 2024 | Impella |
| Aimmune Therapeutics, INC. | $47.24 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $43.22 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.99 | 2020 | |
| Impulse Dynamics (USA) INC. | $36.79 | 2023 | Optimizer |
| Allergan, INC. | $31.98 | 2019 | |
| Viatris Specialty LLC | $24.39 | 2025 | Yupelri |
| Vifor Pharma, INC. | $24.34 | 2019 | |
| Scpharmaceuticals INC. | $22.57 | 2024 | |
| Lundbeck LLC | $21.87 | 2019 | |
| Venclose INC. | $21.27 | 2020 | |
| Medicomp INC | $17.86 | 2020 | |
| Amryt Pharma Holdings LTD | $14.45 | 2021 | |
| Ge Healthcare | $14.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.